The exercise price of expired warrants.

No definition available.

Name:	tnxp_ExercisePriceOfWarrantsExpired
Namespace Prefix:	tnxp_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Period after trading days following the public announcement of the FDA’s acknowledgement and acceptance of the NDA relating to TNX-102 SL product candidate in patients with fibromyalgia for warrant expiration.

+ References

No definition available.

+ Details

Name:	tnxp_PeriodOfTradingDaysAfterFDAAcceptanceOfNDAForWarrantExpiration
Namespace Prefix:	tnxp_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of non-option equity instruments exercised by participants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	instant

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_PrefundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_CommonWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_CommonWarrantsCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_CommonWarrantsDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_CommonWarrantsEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_CommonWarrantsAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=tnxp_CommonWarrantsBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tnxp_SalesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tnxp_PurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

STOCK WARRANTS (Details Narrative) - $ / shares			1 Months Ended	3 Months Ended	12 Months Ended
STOCK WARRANTS (Details Narrative) - $ / shares	Apr. 01, 2024	Dec. 20, 2023	Apr. 01, 2024	Apr. 01, 2024	Dec. 31, 2023	Oct. 03, 2023	Sep. 30, 2023	Jul. 27, 2023
Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrants expired					2,453
Exercise price of warrants expired (in dollars per share)					$ 7,000.00
Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price					$ 0.0001
Pre-Funded Warrants [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	3,900,000		3,900,000	3,900,000
Exercise price	$ 0.0001		$ 0.0001	$ 0.0001
Number of warrants exercised				15,043,244
Common Warrants [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	6,950,000		6,950,000	6,950,000
Exercise price	$ 0.33		$ 0.33	$ 0.33
Termination date	Apr. 01, 2029		Apr. 01, 2029	Apr. 01, 2029
Common Warrants Series C [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	34,823,928		34,823,928	34,823,928
Termination date	Apr. 01, 2026		Apr. 01, 2026	Apr. 01, 2026
Period of trading days after FDA acceptance of NDA for warrant expiration	10 days		10 days
Common Warrants Series D [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	34,823,928		34,823,928	34,823,928
Termination date	Apr. 01, 2029		Apr. 01, 2029	Apr. 01, 2029
Common Warrants Series A [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	14,666,666		14,666,666	14,666,666
Exercise price	$ 0.33		$ 0.33	$ 0.33
Warrants term	5 years 6 months		5 years 6 months	5 years 6 months
Common Warrants Series A [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	8,900,000		8,900,000	8,900,000
Termination date	Apr. 01, 2029		Apr. 01, 2029	Apr. 01, 2029
Common Warrants Series B [Member] \| Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts	8,900,000		8,900,000	8,900,000
Termination date	Apr. 01, 2029		Apr. 01, 2029	Apr. 01, 2029
Sales Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts					28,710,812	4,950,000	4,950,000	4,470,000
Exercise price					$ 0.0001		$ 0.0001	$ 0.0001
Sales Agreement [Member] \| Common Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts							18,000,000	7,000,000
Exercise price							$ 0.50	$ 1.00
Warrants term							5 years	5 years
Sales Agreement [Member] \| Common Warrants Series C [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts					81,081,081
Exercise price					$ 0.555
Warrants term					2 years
Sales Agreement [Member] \| Common Warrants Series D [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts					81,081,081
Exercise price					$ 0.85
Warrants term					5 years
Sales Agreement [Member] \| Common Warrants Series A [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts						9,000,000
Exercise price						$ 0.50
Warrants term						5 years
Sales Agreement [Member] \| Common Warrants Series B [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts						9,000,000
Exercise price						$ 0.50
Purchase Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts		28,710,812
Exercise price		$ 0.0001
Number of warrants exercised		6,509,010			6,509,010
Purchase Agreement [Member] \| Common Warrants Series C [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts		81,081,081
Exercise price		$ 0.555
Warrants term		2 years
Period of trading days after FDA acceptance of NDA for warrant expiration		10 days
Purchase Agreement [Member] \| Common Warrants Series D [Member]
Class of Warrant or Right [Line Items]
Number of shares for common warramts		81,081,081
Exercise price		$ 0.85
Warrants term		5 years